Vitema is a fast-growing Contract Development and Manufacturing Organization (CDMO) based in Sibiu, Romania. With one of the largest GMP-certified pharmaceutical manufacturing facilities in Europe, new management team and assets worth over €100 million, they have ambitious goals.
Ahead of CDMO Live we spoke to Diana Serban, the Head of Commercial and Business Development at Vitema. Diana describes the company as “more than just a CDMO: we are a robust ecosystem that supports the entire pharmaceutical development lifecycle.” This includes everything from the research and development of medicines and food supplements to full-scale production. Vitema also boasts specialised capabilities for oncology products and clinical trials.
Vitema has more than 20 years experience in the pharmaceuticals market, and prides itself on its ability to assist pharmaceutical, biotech, and healthcare companies in delivering high-quality medicines and food supplements to their customers. They offer integrated services, full transparency throughout the entire manufacturing process, and highly competitive pricing data.
2024 growth
2024 has been a year of growth for Vitema. They have capitalised on opportunities by expanding their facility’s capacity and introducing a new production line for powders in response to the growing demand for these formulations.
“There is a substantial shift in consumer behaviour towards natural preventative healthcare, a movement that began during the COVID pandemic and is expected to grow exponentially in the coming years.” says Diana.
Vitema has a significant capacity of 3.5 billion capsules and tablets, 4500 tonnes of powders, and 10 million injectables annually. Given the size of the oral solid market – a form of drug delivery that is both cost-effective and has strong patient compliance – they plan to further expand their production capabilities in this important area.
Diana shares that “in terms of our product portfolio, we just started the technological transfer of 20 new molecules, expanding our offering and ensuring we continue to meet the healthcare needs of a diverse population, especially in critical care segments.”
Diana explains that the company’s strategic foresight has allowed them to navigate the increasing volatility of raw material costs. They secured large-scale acquisitions of key ingredients and stable prices before significant market price increases took effect. This proactive approach has not only stabilised their supply chain but also allowed them to maintain competitive pricing for their clients.
Sustainability
On the sustainability front, Vitema is actively engaged in reducing scope three emissions across their production processes.
They have recently completed the Green Energy Project, financed by EEA and Norwegian funds, which included installing photovoltaic panels. This initiative means they are now able to produce green energy, substantially reducing their carbon footprint.
Find the right partner
“Choosing a CDMO that aligns with your company’s values and shows a genuine passion for your product can significantly enhance the success of your projects.” says Diana.
The Vitema team pride themself on patient-centric approach to development and manufacturing.
“We are deeply committed to going the extra mile to ensure that the products we manufacture not only reach the market but do so in a way that maximises patient benefit”
Meet the Vitema team at CDMO Live, June 13th. Register here for your ticket
Stay ahead of trends and best practices
